Mon, May 12, 8:37 PM (37 days ago)
**Genprex, Inc. (GNPX) Q1 2025 Financial Summary** **Financial Health:** - **Cash Position:** $3.47 million in cash and cash equivalents as of March 31, 2025, up from $1.60 million in December 2024. - **Total Assets:** $6.01 million, including $1.85 million in research and development supplies. - **Liabilities:** $2.14 million in current liabilities, primarily accounts payable and other current liabilities. - **Stockholders' Equity:** $3.87 million, reflecting an increase from $1.62 million in December 2024. **Performance Metrics:** - **Revenue:** No revenue reported for the quarter. - **Operating Expenses:** $3.97 million, down from $6.00 million in Q1 2024. - **Research and Development:** $2.54 million, a 22% decrease from Q1 2024. - **General and Administrative:** $1.43 million, a 47% decrease from Q1 2024. - **Net Loss:** $3.96 million, a 34% decrease from $6.25 million in Q1 2024. - **Earnings per Share:** $(0.26) compared to $(3.86) in Q1 2024. **Cash Flow:** - **Operating Activities:** Net cash used was $4.16 million, a 21% decrease from $5.30 million in Q1 2024. - **Investing Activities:** No cash used in investing activities. - **Financing Activities:** Net cash provided was $6.03 million from the issuance of common stock. **Quarterly Performance Discussion:** - **Expense Reduction:** Significant reductions in travel, professional services, and headcount. - **Clinical Trials:** Continued enrollment in Acclaim-1 and Acclaim-3 trials; Acclaim-2 trial ceased. - **Diabetes Program:** Ongoing preclinical studies and regulatory planning. **Trends and Uncertainties:** - **Funding:** Reliant on equity offerings and ATM facility; uncertainty in raising additional capital. - **Operational Risks:** Dependence on third-party suppliers, regulatory approvals, and market conditions. - **Future Operations:** Focus on completing clinical trials and seeking regulatory approvals. **Impact on Future Operations:** - **Liquidity:** Sufficient cash to fund operations through Q2 2025; uncertainty in maintaining liquidity. - **Strategic Initiatives:** Prioritization of resources, potential strategic collaborations, and internal reorganization. **Nasdaq Compliance:** - **Stockholders' Equity:** Regained compliance with Nasdaq's minimum stockholders' equity requirement. - **Bid Price:** Not compliant with the minimum bid price requirement; monitoring and considering options to regain compliance.